Back to top

Piper Sandler Keeps Their Buy Rating on Kymera Therapeutics (KYMR)

In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on Kymera Therapeutics, with a price target of $140.00. Amin cove...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Kymera Therapeutics, Inc. (KYMR)